Otonomy Inc. buy melinda
Start price
30.08.17
/
50%
€3.49
Target price
13.11.17
€6.31
Performance (%)
33.23%
End price
13.11.17
€4.65
Summary
This prediction ended on 13.11.17 with a price of €4.65. With a performance of 33.23% the BUY prediction by melinda was a big success. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Otonomy Inc. | - | - | - | - |
| iShares Core DAX® | -0.383% | 5.021% | 16.188% | 19.224% |
| iShares Nasdaq 100 | 1.248% | 4.007% | 36.579% | 57.508% |
| iShares Nikkei 225® | 0.525% | -0.109% | 12.378% | 9.329% |
| iShares S&P 500 | 0.640% | 3.649% | 28.752% | 47.932% |
Comments by melinda for this prediction
In the thread Otonomy Inc. diskutieren
Hersteller von Arzneimitteln
30. August (Reuters) - US - Arzneimittelhersteller Otonomy Inc. sagte am Mittwoch , dass seine Droge Meniere-Krankheit, eine chronische Erkrankung des Innenohrs zu behandeln, das Hauptziel in einer späten Studie fehlt.